<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014092</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067958</org_study_id>
    <secondary_id>SFMH-BB-IND-5301</secondary_id>
    <secondary_id>NCI-V00-1591</secondary_id>
    <nct_id>NCT00014092</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery</brief_title>
  <official_title>Treatment of Patients With Metastatic Malignant Melanoma With Chemobiotherapy With Temozolomide, GM-CSF, IL2, and Interferon Alfa-2b Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Francis Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Biological therapies such as interleukin-2 and interferon alfa&#xD;
      stimulate a person's white blood cells to kill cancer cells or may interfere with the growth&#xD;
      of cancer cells. Combining chemotherapy with biological therapies may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of temozolomide followed by sargramostim,&#xD;
      interleukin-2, and interferon alfa in treating patients who have stage IV melanoma that&#xD;
      cannot be treated with surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate, time to progression, and survival of patients with&#xD;
           unresectable stage IV melanoma treated with temozolomide followed by sargramostim&#xD;
           (GM-CSF), interleukin-2, and interferon alfa.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in this patient population.&#xD;
&#xD;
        -  Determine the changes in quality of life over time in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral temozolomide on days 1-5, and sargramostim (GM-CSF), interleukin-2, and&#xD;
      interferon alfa subcutaneously on days 6-17. Treatment repeats every 28 days for 4-8 courses&#xD;
      in the absence of disease progression or unacceptable toxicity. Patients with at least stable&#xD;
      or responsive disease after 8 courses of therapy may receive additional therapy at&#xD;
      investigators discretion.&#xD;
&#xD;
      Quality of life is assessed at baseline, every 8 weeks during study, and then at 1 month&#xD;
      after study.&#xD;
&#xD;
      Patients are followed at 1 month, every 3 months for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed unresectable stage IV melanoma&#xD;
&#xD;
          -  Measurable metastatic disease&#xD;
&#xD;
          -  No uncontrolled brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT no greater than 3 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 3 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN no greater than 1.5 times ULN&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant cardiovascular disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No non-malignant systemic disease&#xD;
&#xD;
          -  No acute infection requiring IV antibiotics&#xD;
&#xD;
          -  No alcohol or substance abuse&#xD;
&#xD;
          -  No other condition, disease, or history of other illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No hypersensitivity, allergic reactions, or intolerance to study drugs&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No prior interleukin-2&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent investigational vaccines or immunomodulatory agents&#xD;
&#xD;
          -  No other concurrent growth factors&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior temozolomide&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent steroids (including corticosteroids)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior immune-based therapy&#xD;
&#xD;
          -  No concurrent participation in other clinical trials with investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer drugs&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
&#xD;
          -  No concurrent levamisole or cimetidine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn E. Spitler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Northern California Melanoma Center at St. Francis Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Francis Memorial Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute at Saint John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Weber RW, O'Day S, Rose M, Deck R, Ames P, Good J, Meyer J, Allen R, Trautvetter S, Timmerman M, Cruickshank S, Cook M, Gonzalez R, Spitler LE. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol. 2005 Dec 10;23(35):8992-9000. Epub 2005 Oct 31.</citation>
    <PMID>16260693</PMID>
  </results_reference>
  <verification_date>March 2004</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

